Complement inhibition in severe COVID-19 – Blocking C5a seems to be key: Author's reply

• Djillali Annane,
• Lamiae Grimaldi-Bensouda,
• Véronique Fremeaux-Bacchic

Affiliations

Djillali Annane

Department of Intensive Care, Hôpital Raymond Poincaré (APHP), Laboratory of Infection & Inflammation _ U1173, School of Medicine Simone Veil, University Versailles Saint Quentin _ University Paris Saclay, INSERM, FHU SEPSIS (Saclay and Paris Seine Nord Endeavour to PerSonalize Interventions for Sepsis), RHU RECORDS (Rapid rEcognition of CORticosteroiD resistant or sensitive Sepsis), 104 Boulevard Raymond Poincaré, Garches 92380, France; Corresponding author.

Lamiae Grimaldi-Bensouda

Clinical Research Unit AP-HP, Paris-Saclay, H^opital Raymond Poincar_e, School of Medicine Simone Veil, University Versailles Saint Quentin, University Paris, Saclay, INSERM, CESP Anti-Infective Evasion and Pharmacoepidemiology Team, F-78180 Montigny-Le-Bretonneux, France

Véronique Fremeaux-Bacchic

Laboratory of Immunology, Georges-Pompidou European Hospital (APHP), Invasive Bacterial Infection Unit and National Reference Center for Meningococci, Pasteur, Institute, Centre de Recherche des Cordeliers, Paris, France